BRISTOL MYERS SQUIBB CO
CELG-RIDrugs in Pipeline
242
Phase 3 Programs
122
Upcoming Catalysts
16
Next Catalyst
May 31, 2026
6wMarket Overview
Stock performance and key metrics
17 upcoming, 1 past
Opdivo
Renal Cell Carcinoma
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Capecitabine
Gastric Cancer
Asunaprevir (ASV)
Hepatitis C Virus
Leucovorin
Metastatic Colorectal Cancer
Antidepressant + Aripiprazole
Major Depressive Disorder
BMS-936558
Unresectable or Metastatic Melanoma
Asunaprevir
Hepatitis C
DCV
Hepatitis C
Entecavir
Hepatitis B, Chronic
Relatlimab
Advanced Gastric Cancer
Cisplatin
Non Small Cell Lung Cancer
Videx EC
HIV Infections
Paclitaxel
Breast Cancer
Daclatasvir
Hepatitis C Infection
Etoposide
Small Cell Lung Carcinoma
Apremilast
Psoriatic Arthritis
Ustekinumab
Plaque Psoriasis
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Tenofovir
Chronic Hepatitis B
Oxaliplatin
Colorectal Cancer
BMS-986205
Advanced Cancer
Muraglitazar
Metabolics Diabetes Nos
Oral Azacitidine
Myelodysplastic Syndromes
Imatinib
Chronic Myeloid Leukemia
Atazanavir (immediate switch)
HIV Infections
Telaprevir
Hepatitis C
Cabozantinib
Renal Cell Carcinoma
Cyclosporine (CsA)
Kidney Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Carboplatin
Pediatric Solid Tumors
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Prednisone
Prostate Cancer
Elotuzumab
Multiple Myeloma
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
Sorafenib
Hepatocellular Carcinoma
Ribavirin
Hepatitis C
Atazanavir
HIV Infections
Lamivudine/Zidovudine
HIV Infections
Methotrexate
Rheumatoid Arthritis
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
Adalimumab
Rheumatoid Arthritis
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Dacarbazine
Melanoma
Everolimus
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Peginterferon Alfa-2a
Hepatitis C
pexacerfont
Generalized Anxiety Disorder
SAR302503
Hematopoietic Neoplasm
Peg-interferon Alfa-2a
Hepatitis C Virus
Gemcitabine
Stage IV or Recurrent Non-Small Cell Lung Cancer
Iza-bren
Urothelial Cancer
Didanosine
HIV Infections
vinflunine
Transitional Cell Carcinoma
rHuPH20
Melanoma
Enoxaparin
Deep Vein Thrombosis
Stavudine
HIV Infections
Irbesartan monotherapy
Hypertension
Epoetin Alfa
Myelodysplastic Syndromes
Bempegaldesleukin
Bladder Cancer
Pemetrexed
Mesothelioma, Malignant
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
Fluorouracil
Various Advanced Cancer
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Iberdomide
Multiple Myeloma
Atazanavir powder
HIV Infections
Sunitinib
Advanced Renal Cell Carcinoma
Atazanavir Sulphate
HIV
Deucravacitinib
Psoriatic Arthritis
Glucovance (metformin HCl/glyburide)
Diabetes Mellitus, Non-Insulin-Dependent
ATV
HIV Infections
Pomalidomide
Multiple Myeloma
Atazanavir+ritonavir
HIV Infections
Pegylated-Interferon-lambda
Hepatitis C Virus
Atazanvir/ritonavir + efavirenz
HIV Infections
Lenalidomide
Multiple Myeloma
Bortezomib
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
Belatacept
Renal Transplantation
Tacrolimus
Renal Allograft Recipients
Tanespimycin
Advanced Malignancies
Abatacept subcutaneous
Polymyositis
PEG-Interferon alfa 2a
Hepatitis C, Genotype 1
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
Docetaxel
Non-Small Cell Lung Cancer
Sorivudine
HIV Infections
Mavacamten
Cardiomyopathy, Hypertrophic
KarX-EC
Alzheimer's Disease
Double-blind Abatacept
Rheumatoid Arthritis
Apixaban
Lymphoma
Pioglitazone
Type 2 Diabetes Mellitus
BMS-986165
Psoriasis
warfarin
Venous Thrombosis
KarXT
Alzheimer Disease
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Atazanavir/Ritonavir
HIV
Xanomeline/Trospium Chloride
Mania
Efavirenz
HIV Infections
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
Xanomeline Enteric Capsule
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Temozolomide
Brain Cancer
nab-Paclitaxel
Non-Small Cell Lung Cancer
DCV 3DAA
Hepatitis C Virus Infection
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
dasatinib
Myeloid Leukemia, Chronic, Accelerated Phase
Abatacept
Rheumatoid Arthritis
Pumitamig
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
Simeprevir
Hepatitis C Virus
BMS-754807
Breast Cancer
Aurexis®
Staphylococcus Aureus Bacteremia
Vitamin K Antagonist (VKA)
Thrombosis
Letrozole
Metastatic Breast Cancer
CXL-1020
Heart Failure
Oral Taxane
Non-small Cell Lung Cancer
BMS-986253
Cancer
BMS-986322
Psoriasis
BMS-986490
Advanced Solid Tumors
MYK-491
Heart Failure With Reduced Ejection Fraction
PSI-7977
Chronic Hepatitis C
200 mg INX-08189 Fasted
Hepatitis C
unfractionated heparin (UFH)
Antithrombotic
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
Duloxetine
Depression
MDX-1100
Rheumatoid Arthritis
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
BMS-986158
Myelofibrosis
BMS-986020
Idiopathic Pulmonary Fibrosis
BMS-830216
Obesity
Strata 1 CXL-1020
Heart Failure
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
Anastrozole
Breast Cancer
BMS-986446
Alzheimer Disease, Early Onset
SAR302503 (TG101348)
Myelofibrosis
HNO Donor
Heart Failure
BMS-986435
Heart Failure
ixabepilone
Esophageal Cancer
Cyclophosphamide
Breast Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
BMS-986156
Solid Tumors
MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
Lamivudine
Hepatitis B Virus
BMS-986458
Relapsed/Refractory Non-Hodgkin Lymphoma
Thymoglobulin
Kidney Transplantation
BMS-690514
Non-Small-Cell Lung Carcinoma
Cyclosporine A
Renal Transplant
Ritonavir
HIV Infections
Dexamethasone
Multiple Myeloma
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-986288
Advanced Cancer
BMS-650032
Hepatitis C Virus
CC-486
Leukemia, Myeloid, Acute
BMS-986141
Thrombosis
Aurexis® (tefibazumab)
Staphylococcus Aureus
Cabazitaxel
Prostate Cancer
Pegylated Interferon Lambda
Hepatitis C
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
BMS-986369
Relapsed or Refractory T-cell Lymphomas
5-fluorouracil (5-FU)
Colorectal Cancer
Peginterferon alpha-2a
Hepatitis C Infection
Exemestane + Dasatinib
Breast Cancer
Dasatinib 100 mg
Breast Cancer
MDX-010
Breast Cancer
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
Vemurafenib
Melanoma
KOS-1584
Non-Small Cell Lung Cancer
INX-08189 50 mg
Healthy
Pegylated-interferon alfa-2a
Chronic Hepatitis C
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
BMS-986482
Advanced Solid Tumors
BMS-791325
Hepatitis C Virus
Daratumumab
Advanced Cancer
BMS-562086
Irritable Bowel Syndrome
Elotuzumab (BMS-901608)
Multiple Myeloma
BMS-986012
Extensive-stage Small Cell Lung Cancer
BMS-833923
Leukemia
BMS-986165 Dose A
Active Psoriatic Arthritis
BMS-986315
Advanced Solid Tumor
BMS-986470
Anemia, Sickle Cell
BMS-790052 (NS5A Inhibitor)
Hepatitis C
BMS-986525
Relapsed/Refractory Small Cell Lung Cancer
BMS-813160
Advanced Cancer
Sirolimus
Disorder Related to Renal Transplantation
BMS-914392
Atrial Fibrillation
Erlotinib
Non Small Cell Lung Cancer
branebrutinib
Autoimmune Disorder
Fulvestrant
Advanced Breast Cancer
Megestrol acetate
Anorexia
BMS-582949
Vascular Diseases
Cobimetinib
Microsatellite Unstable Colorectal Cancer
Afimetoran
Systemic Lupus Erythematosus
BMS-820836
Depression
pegIFN
Hepatitis B Virus
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
BMS-986449
Advanced Solid Tumors
Pegylated interferon alfa-2a
Hepatitis C Virus
Cyclosporine
Graft Rejection
Irinotecan
Colorectal Cancer (CRC)
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
BMS-777607
Advanced Solid Tumors
Fedratinib
Primary Myelofibrosis
BMS-986231
Cardiac Failure
BMS-770767
Diabetes Type 2
BMS-986507
Lung Cancer
BMS-986263
Hepatic Cirrhosis
INX-08189 50 mg QD X 5 days
Healthy
bendamustine
Hodgkin Disease
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
brivanib (active)
Hepatocellular Carcinoma (HCC)
MDX-010 (CTLA-4)
Melanoma
BMS-986249
Advanced Cancer
BMS-986207
Broad Solid Tumor
BMS-986517
Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Opdivo | Approved | Renal Cell Carcinoma | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Leucovorin | Phase 3 | Metastatic Colorectal Cancer | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Cisplatin | Phase 3 | Non Small Cell Lung Cancer | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Paclitaxel | Phase 3 | Breast Cancer | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Ustekinumab | Phase 3 | Plaque Psoriasis | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Imatinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma | - | - |
Cyclosporine (CsA) | Phase 3 | Kidney Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Carboplatin | Phase 3 | Pediatric Solid Tumors | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Prednisone | Phase 3 | Prostate Cancer | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Everolimus | Phase 3 | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | - | - |
Peginterferon Alfa-2a | Phase 3 | Hepatitis C | - | - |
pexacerfont | Phase 3 | Generalized Anxiety Disorder | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Gemcitabine | Phase 3 | Stage IV or Recurrent Non-Small Cell Lung Cancer | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
Didanosine | Phase 3 | HIV Infections | - | - |
vinflunine | Phase 3 | Transitional Cell Carcinoma | - | - |
rHuPH20 | Phase 3 | Melanoma | - | - |
Enoxaparin | Phase 3 | Deep Vein Thrombosis | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Pemetrexed | Phase 3 | Mesothelioma, Malignant | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Fluorouracil | Phase 3 | Various Advanced Cancer | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
Atazanavir powder | Phase 3 | HIV Infections | - | - |
Sunitinib | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Glucovance (metformin HCl/glyburide) | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ATV | Phase 3 | HIV Infections | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Atazanavir+ritonavir | Phase 3 | HIV Infections | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
Atazanvir/ritonavir + efavirenz | Phase 3 | HIV Infections | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Belatacept | Phase 3 | Renal Transplantation | - | - |
Tacrolimus | Phase 3 | Renal Allograft Recipients | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
Abatacept subcutaneous | Phase 3 | Polymyositis | - | - |
PEG-Interferon alfa 2a | Phase 3 | Hepatitis C, Genotype 1 | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
warfarin | Phase 3 | Venous Thrombosis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
Xanomeline/Trospium Chloride | Phase 3 | Mania | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Temozolomide | Phase 3 | Brain Cancer | - | - |
nab-Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
dasatinib | Phase 3 | Myeloid Leukemia, Chronic, Accelerated Phase | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
Simeprevir | Phase 2 | Hepatitis C Virus | - | - |
BMS-754807 | Phase 2 | Breast Cancer | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
Letrozole | Phase 2 | Metastatic Breast Cancer | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
Oral Taxane | Phase 2 | Non-small Cell Lung Cancer | - | - |
BMS-986253 | Phase 2 | Cancer | - | - |
BMS-986322 | Phase 2 | Psoriasis | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Duloxetine | Phase 2 | Depression | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
Strata 1 CXL-1020 | Phase 2 | Heart Failure | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
Anastrozole | Phase 2 | Breast Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
Cyclophosphamide | Phase 2 | Breast Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
BMS-986156 | Phase 2 | Solid Tumors | - | - |
MDX-010 / MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
Lamivudine | Phase 2 | Hepatitis B Virus | - | - |
BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Cyclosporine A | Phase 2 | Renal Transplant | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986288 | Phase 2 | Advanced Cancer | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
CC-486 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
BMS-986141 | Phase 2 | Thrombosis | - | - |
Aurexis® (tefibazumab) | Phase 2 | Staphylococcus Aureus | - | - |
Cabazitaxel | Phase 2 | Prostate Cancer | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
5-fluorouracil (5-FU) | Phase 2 | Colorectal Cancer | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |
Daratumumab | Phase 2 | Advanced Cancer | - | - |
BMS-562086 | Phase 2 | Irritable Bowel Syndrome | - | - |
Elotuzumab (BMS-901608) | Phase 2 | Multiple Myeloma | - | - |
BMS-986012 | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
BMS-833923 | Phase 2 | Leukemia | - | - |
BMS-986165 Dose A | Phase 2 | Active Psoriatic Arthritis | - | - |
BMS-986315 | Phase 2 | Advanced Solid Tumor | - | - |
BMS-986470 | Phase 2 | Anemia, Sickle Cell | - | - |
BMS-790052 (NS5A Inhibitor) | Phase 2 | Hepatitis C | - | - |
BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | - | - |
BMS-813160 | Phase 2 | Advanced Cancer | - | - |
Sirolimus | Phase 2 | Disorder Related to Renal Transplantation | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
Erlotinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Fulvestrant | Phase 2 | Advanced Breast Cancer | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
BMS-820836 | Phase 2 | Depression | - | - |
pegIFN | Phase 2 | Hepatitis B Virus | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
BMS-986449 | Phase 2 | Advanced Solid Tumors | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
Irinotecan | Phase 2 | Colorectal Cancer (CRC) | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
BMS-777607 | Phase 2 | Advanced Solid Tumors | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
MDX-010 (CTLA-4) | Phase 2 | Melanoma | - | - |
BMS-986249 | Phase 2 | Advanced Cancer | - | - |
BMS-986207 | Phase 2 | Broad Solid Tumor | - | - |
BMS-986517 | Phase 2 | Solid Tumours | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)